Whitehawk Therapeutics Q3 Net Loss Widens on R&D Expenses
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…
Story updates
01:13:28 PM UTC
SquawkNews
Whitehawk Therapeutics reported a net loss of $21.2 million for the third quarter of 2026, compared with a $17.7 million loss a year earlier. Revenue was zero, while research and development expenses rose to $18.1 million. The company had $169.7 million in cash, cash equivalents and short-term inve…
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…